Rating History for Gilead Sciences (GILD) by Barclays
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 2/19/2026 | Carter Gould | New Coverage | Equalweight (N/A) |
155.00 (N/A) |
152.74 (135.82) |
-11.08% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 2/19/2026 | Carter Gould | New Coverage | Equalweight (N/A) |
155.00 (N/A) |
152.74 (135.82) |
-11.08% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||